Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 715 results

Media Release / Nov 15, 2016

New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
Media Release / Nov 10, 2016

Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting

This is the latest addition to the Alcon AIR OPTIX® portfolio of monthly replacement contact lenses which merges two unique technologiesSmartShield® Technology provides excellent deposit resistance…
Media Release / Nov 10, 2016

Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
Media Release / Nov 10, 2016

Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones

Together in HF social network is an innovative resource for information and support and a place to meet others with similar health experiencesNearly 6 million Americans have heart failure (HF), a…
Media Release / Nov 10, 2016

Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
Media Release / Oct 01, 2016

Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years

-- New data at EADV show Cosentyx delivers almost clear or completely clear skin in majority of patients (PASI 90 - 66%, PASI 100 - 44%) after four years of treatment1-- Data show that with Cosentyx…
Media Release / Oct 01, 2016

Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
Media Release / Sep 23, 2016

Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions

- Ilaris® (canakinumab) is the first and only FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF(1)- These three simultaneous approvals conducted under FDA Priority Review…
Media Release / Sep 23, 2016

Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
Media Release / Sep 19, 2016

Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients

New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…

‹ Previous page
1
…
42
43
44
45
46
47
48
…
72
› Next page